

16<sup>th</sup> World Congress on Cancers of the Skin®  
12<sup>th</sup> Congress of the European Association of Dermato-Oncology

AUGUST 31 – SEPTEMBER 3, 2016  
VIENNA, AUSTRIA



Saturday, September 3, 2016

Time	Festsaal	Zeremoniensaal	Rittersaal
8:00 AM – 9:00 AM	<b>SY38</b> <b>Side Effects of Systemic Skin Cancer Therapies</b> <i>Chairs:</i> <i>K. Schindler (Vienna, Austria)</i> <i>C. Loquai (Mainz, Germany)</i>	<b>SY39</b> <b>Current Standard of Imaging Methods for Skin Cancer Patients</b> <i>Chairs:</i> <i>N. Schwenzer (Tuebingen, Germany)</i> <i>M. Mayerhoefer (Vienna, Austria)</i>	
	<b>SY38-1</b> Side effects of systemic therapies for NMSC 8:00 AM <i>C. Loquai (Mainz, Germany)</i>	<b>SY39-1</b> Whole-body staging of melanoma 8:00 AM <i>N. Schwenzer (Tuebingen, Germany)</i>	
	<b>SY38-2</b> Side effects of targeted therapies for metastatic melanoma (BRAF/MEK) 8:15 AM <i>C. Lebbe (Paris, France)</i>	<b>SY39-2</b> Treatment response assessment in melanoma 8:15 AM <i>M. Mayerhoefer (Vienna, Austria)</i>	
	<b>SY38-3</b> Side effects of immunotherapies for metastatic melanoma 8:30 AM <i>K. Schindler (Vienna, Austria)</i>	<b>SY39-3</b> Radiopharmaceuticals for molecular imaging of melanoma 8:30 AM <i>M. Mitterhauser (Vienna, Austria)</i> <i>W. Wadsak (Vienna, Austria)</i>	
	<b>SY38-4</b> <i>Discussion: How will future combinations impact side effect management?</i> 8:45 AM		
9:00 AM – 10:00 AM	<b>FC3</b> <b>C. Posch, C. Hoeller</b>	<b>FC2</b> <b>A. Steiner, H. Pehamberger</b>	
	<b>FC3-1</b> Targeted characterization of advanced melanoma cases at diagnosis uncovers case-specific malignant networks involving MAPK-dependent and MAPK-independent mechanisms of disease 09:00 AM <i>S. Curiel-Olmo (Santander, Spain)</i>	<b>FC2-1</b> Inverse association between atopy and melanoma: a case-control study 09:00 AM <i>V. Marasigan (Leuven, Belgium)</i>	
	<b>FC3-2</b> Response patterns to MEK inhibition, but not NRAS mutation status predict the efficacy of combined MEK/CDK4,6 targeting in melanoma 09:12 AM <i>C. Posch (Vienna, Austria)</i>	<b>FC2-2</b> Impact of adjuvant immunotherapy on survival of patients with resected stage III melanoma diagnosed in 2003-2011 in the US 09:12 AM <i>S. Jang (Fairfax, VA, USA)</i>	
	<b>FC3-3</b> Incidence, course, and management of toxicities associated with cobimetinib combined with vemurafenib in the cobrim study: an updated analysis 09:24 AM <i>B. Dreno (Nantes, France)</i>	<b>FC2-3</b> Treatment efficacy with electrochemotherapy: a multi-institutional prospective observational study on 376 patients with superficial tumors 09:24 AM <i>L. G. Campana (Padova, Italy)</i>	
	<b>FC3-4</b> Basal cell carcinoma cancer stem cells promote immune evasion 09:36 AM <i>G. Patel (Cardiff, UK)</i>	<b>FC2-4</b> Sun protection after melanoma diagnosis improves survival 09:36 AM <i>M. Mueller (Vienna, Austria)</i>	
	<b>FC3-5</b> TBA 09:48 AM	<b>FC2-5</b> Evaluation of 5-fluorouracil 0.5% / salicylic acid 10% in the field-directed treatment of actinic keratosis: a phase III, randomised, vehicle-controlled trial 09:48 AM <i>E. Stockfleth (Bochum, Germany)</i>	
10:00 AM – 10:30 AM	<b>Coffee Break</b>		
10:30 AM – 11:30 AM	<b>SY40</b> <b>Predictive Biomarkers in Melanoma</b> <i>Chairs:</i> <i>J. Becker (Essen, Germany)</i> <i>C. Krepler (Philadelphia, USA)</i>	<b>SY41</b> <b>New Methods in Early Detection of Skin Cancer</b> <i>Chairs:</i> <i>G. Pellacani (Modena, Italy)</i> <i>P. Soyer (Brisbane, Australia)</i>	<b>SY42</b> <b>Brain Metastases</b> <i>Chairs:</i> <i>M. Preusser (Vienna, Austria)</i> <i>F. Winkler (Heidelberg, Germany)</i>

	<b>SY40-1</b> 10:30 AM	What should an ideal biomarker look like? J. Becker (Essen, Germany)	<b>SY41-1</b> 10:30 AM	Confocal microscopy/multiphoton imaging G. Pellacani (Modena, Italy)	<b>SY42-1</b> 10:30 AM	Biology of brain metastases A. Berghoff (Vienna, Austria)
	<b>SY40-2</b> 10:50 AM	Biomarkers for targeted therapies beyond b-raf status D. Schadendorf (Essen, Germany)	<b>SY41-2</b> 10:45 AM	Electric impedance spectroscopy J. Malvehy (Barcelona, Spain)	<b>SY42-2</b> 10:45 AM	The leptomeningeal microenvironment as protective sanctuary for melanoma cells I. Fedorenko (Tampa, USA)
	<b>SY40-3</b> 11:10 AM	Preclinical evaluation of biomarkers to predict therapeutic response C. Krepler (Philadelphia, USA)	<b>SY41-3</b> 11:00 AM	Total body photography A. Halpern (New York, USA)	<b>SY42-3</b> 11:00 AM	How do the new therapies influence our algorithms for brain metastases? M. Preusser (Vienna, Austria)
			<b>SY41-4</b> 11:15 AM	"Apps" and telemedicine H. P. Soyer (Brisbane, Australia)	<b>SY42-4</b> 11:15 AM	Surgery for brain metastases from cutaneous tumors J.-C. Tonn (Munich, Germany)
<b>11:35 AM – 12:05 PM</b>	<b>PL5</b>	<b>Future Targets and Combinations</b>				
	<i>Chairs:</i>	<i>H. Pehamberger (Vienna, Austria)</i> <i>C. Hoeller (Vienna, Austria)</i>				
	<b>PL5-1</b>	The future of dermatooncology C. Garbe (Tuebingen, Germany)				
<b>12:05 PM – 12:30 PM</b>	<b>OT4</b>	<b>Closing Ceremony</b>				
		<i>C. Hoeller (Vienna, Austria)</i>				